RNA Atrium Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2093101 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.3%
Debt / equity0.00x
Current ratio10.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $15.32M | $3.00M | $19.64M | $12.34M | $3.85M | $1.57M |
| R&D expense | $13.80M | $15.34M | $16.66M | $9.75M | $13.29M | $6.94M |
| SG&A expense | $8.15M | $10.28M | $20.26M | $2.80M | $3.42M | $2.09M |
| Operating income | -$6.63M | -$22.62M | -$17.28M | -$213,000 | -$12.86M | -$7.45M |
| Pretax income | -$4.27M | — | — | -$213,000 | — | — |
| Income tax | $0 | — | — | -$176,000 | — | — |
| Net income | -$4.27M | -$20.19M | -$16.63M | -$37,000 | -$12.88M | -$7.45M |
| EBITDA | -$6.28M | -$22.27M | -$17.13M | -$144,000 | -$12.79M | -$7.40M |
| EPS (basic) | -0.25 | -1.18 | -0.97 | 0.00 | -0.75 | -0.44 |
| EPS (diluted) | -0.25 | -1.18 | -0.97 | 0.00 | -0.75 | -0.44 |
| Weighted avg. shares (diluted) | 17.04M | 17.11M | 17.11M | 17.11M | 17.11M | 17.11M |
| Balance sheet | ||||||
| Cash & equivalents | $44.56M | $72.33M | $267.85M | $0 | $0 | $0 |
| Short-term investments | $187.51M | $191.57M | — | — | — | — |
| Current assets | $258.05M | $275.05M | $285.56M | — | — | — |
| PP&E, net | $4.19M | $4.07M | $4.34M | — | — | — |
| Total assets | $263.99M | $280.51M | $292.36M | — | — | — |
| Current liabilities | $24.66M | $31.51M | $21.91M | — | — | — |
| Total liabilities | $58.97M | $65.94M | $58.26M | — | — | — |
| Shareholders' equity | $205.02M | $214.58M | $234.10M | -$57.15M | -$56.18M | -$56.30M |
| Shares outstanding | 16.40M | 17.11M | 17.11M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$25.37M | -$3.93M | -$31.14M | $1.13M | -$11.91M | -$11.10M |
| Capital expenditure | $415,000 | $36,000 | $2.10M | $300,000 | $266,000 | $0 |
| Free cash flow | -$25.78M | -$3.96M | -$33.24M | $833,000 | -$12.17M | -$11.10M |
| Investing cash flow | $3.90M | -$191.59M | -$2.10M | -$300,000 | -$266,000 | $0 |
| Financing cash flow | -$6.30M | $0 | $301.50M | -$833,000 | $12.17M | $11.10M |
| Depreciation & amortization | $352,000 | $343,000 | $151,000 | $69,000 | $79,000 | $53,000 |
| Stock-based compensation | $1.12M | $893,000 | $12.21M | $1.22M | $1.70M | $1.21M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.